Novartis Animal Health announces the introduction of Florvio (florfenicol) 2.3% Concentrate Solution for fast-acting and effective treatment of swine respiratory disease (SRD). Florvio is a broad-spectrum antibiotic indicated for the treatment of SRD associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Streptococcus suis and Salmonella choleraesuis.
The active ingredient in Florvio — florfenicol — is well-researched in pigs and has a proven track record of efficacy and safety, Novartis Animal Health said. Clinical studies and field trials have shown that florfenicol can significantly improve treatment success of SRD and quickly reduce clinical signs of disease, the announcement said.
“Florvio combines several of the key attributes veterinarians most commonly look for in an antibiotic for treating pigs diagnosed with respiratory disease,” said Mike Daly, farm animal brand manager for Novartis Animal Health. “It’s broad spectrum, fast-acting and the active ingredient in Florvio is used only in veterinary medicine. Consequently, it’s not classified as important for human medicine and that’s a benefit both veterinarians and producers appreciate.”
As a liquid concentrate, Florvio is administered in the water supply. It is intended for treating respiratory disease in nursery pigs from eight to 13 weeks of age.